IL1B and systemic lupus erythematosus: Genetically modified BM-MSCs to overexpress IL-37 showed in vitro suppression of splenocyte proliferation, decreasing cytokines IL-1β, TNF-α, IL-17, and IL-6 and autoantibodies leading to an improvement of SLE signs in a mouse model (211).